<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677439</url>
  </required_header>
  <id_info>
    <org_study_id>Flumatinib20201216</org_study_id>
    <nct_id>NCT04677439</nct_id>
  </id_info>
  <brief_title>Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure</brief_title>
  <official_title>Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hainan General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanya Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Shantou University Medical Collegeity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of flumatinib in chronic&#xD;
      phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, single-arm, prospective, open-label study to detect the efficacy and safety of&#xD;
      flumatinib by measuring rates of major molecular response (MMR) at 12 months in CML-CP&#xD;
      patients with Ph+ in China. Approximately 200 Patients will be recruited consecutively from&#xD;
      the study sites during the enrollment period and will be given flumatinib 600 mg QD. The&#xD;
      duration of patient participation will be 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test.</measure>
    <time_frame>12 months</time_frame>
    <description>Major molecular response (MMR) is defined as BCR-ABL1 ≤ 0.1 percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MR 4.0 at 3, 6, 9, 12 months.</measure>
    <time_frame>3, 6, 9, 12 months.</time_frame>
    <description>Molecular response (MR) 4.0 is defined as BCR-ABL transcripts ≤ 0.01 percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MR 4.5 at 3, 6, 9, 12 months.</measure>
    <time_frame>3, 6, 9, 12 months.</time_frame>
    <description>Molecular response (MR) 4.5 is defined as BCR-ABL transcripts ≤ 0.0032 percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MMR at 3, 6, 9 months.</measure>
    <time_frame>3, 6, 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs) to Flumatinib.</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of adverse events (AEs), serious AEs (SAEs), and clinically relevant changes in laboratory tests according to laboratory reference ranges.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Flumatinib</condition>
  <condition>Chronic Myeloid Leukemia, Chronic Phase</condition>
  <condition>Imatinib</condition>
  <arm_group>
    <arm_group_label>Flumatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumatinib</intervention_name>
    <description>600 mg of Flumatinib orally daily for 24 months</description>
    <arm_group_label>Flumatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Diagnosis of CML-CP with Ph+.&#xD;
&#xD;
          -  ECOG performance of 0-2.&#xD;
&#xD;
          -  Adequate end organ function defined as the following: total bilirubin &lt;1.5x ULN, SGPT&#xD;
             &lt;2.5x ULN, creatinine &lt;1.5x ULN.&#xD;
&#xD;
          -  Treatment failure after imatinib at 3 or 6 months with BCR-ABL &gt;10%.&#xD;
&#xD;
          -  Patients must sign an informed consent form (ICF) indicating they are aware of the&#xD;
             investigational nature of this study, in keeping with the policies of the hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously documented T315I mutation.&#xD;
&#xD;
          -  History of TKI treatments except of imatinib.&#xD;
&#xD;
          -  History of undergone major surgery within 4 weeks.&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol.&#xD;
&#xD;
          -  Pregnant or breast-feeding patients.&#xD;
&#xD;
          -  patients with other malignant tumor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Du, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Second People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Du, Phd</last_name>
    <phone>075583366388</phone>
    <email>duxingz@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second People's Hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flumatinib, CML-CP with Ph+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HH-GV-678</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

